Table 2. Seroprevalence of IgG against protoparvoviruses in different population cohorts*.
| Cohort | No. persons | Any bufavirus IgG† | IgG against bufavirus genotypes |
Tusavirus IgG | Cutavirus IgG‡ | ||
|---|---|---|---|---|---|---|---|
| 1 | 2‡ | 3 | |||||
| Finland, healthy adults (veterinarians) | 324 | 6 (1.9) | 4 (1.2) | 1 (0.3)§ | 1 (0.3) | 0 | 16 (4.9)§ |
| United States, healthy adults | 84 | 3 (3.6) | 0 | 0 | 3 (3.6) | 0 | 0 |
| Iraq, healthy adults | 99 | 84 (84.8) | 80 (80.8) | 33 (33.3)¶ | 15 (15.2) | 0 | 1 (1.0)¶ |
| Iran, healthy adults | 107 | 60 (56.1) | 55 (51.4) | 17 (17.9) | 6 (5.6) | 0 | 6 (5.6) |
| Kenya, febrile children <18 y of age | 107 | 22 (20.6) | 3 (2.8) | 4 (3.7) | 20 (18.7) | 0 | 2 (1.9) |
| Kenya, febrile adults | 119 | 86 (72.3) | 31 (26.1) | 43 (36.1)# | 56 (47.1) | 0 | 5 (4.2)# |
*Values are no. (%) unless otherwise noted.. †Includes persons that were IgG+ against >1 bufavirus genotypes. ‡Unclear bufavirus 2 and cutavirus blocking results were observed for 1§ (0.3%), 2¶ (2.0%), and 3# (2.5%) persons. These values are not included in overall seroprevalence calculations.